These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25287169)

  • 1. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
    Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
    Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.
    Hyeon J; Ahn S; Lee JJ; Song DH; Park CK
    Dig Dis Sci; 2013 Jul; 58(7):1916-22. PubMed ID: 23456506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
    Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
    Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
    Xie C; Ye X; Zeng L; Zeng X; Cao D
    J Gastroenterol; 2023 Oct; 58(10):1030-1042. PubMed ID: 37500927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Wu CY; Jan YJ; Ko BS; Wu YJ; Wu YJ; Liou JY
    Anticancer Res; 2018 Dec; 38(12):6855-6863. PubMed ID: 30504401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
    Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
    Liu Z; Yan R; Al-Salman A; Shen Y; Bu Y; Ma J; Luo DX; Huang C; Jiang Y; Wilber A; Mo YY; Huang MC; Zhao Y; Cao D
    Biochem J; 2012 Mar; 442(2):273-82. PubMed ID: 22329800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
    Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
    Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
    Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
    Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
    Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
    Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
    Matkowskyj KA; Bai H; Liao J; Zhang W; Li H; Rao S; Omary R; Yang GY
    Hum Pathol; 2014 Apr; 45(4):834-43. PubMed ID: 24656094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.
    Wang Z; Pei Y; Li W; Zhang J; Liu J
    PLoS One; 2022; 17(12):e0279591. PubMed ID: 36584078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
    Tsuzura H; Genda T; Sato S; Murata A; Kanemitsu Y; Narita Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Ichida T
    Int J Mol Sci; 2014 Apr; 15(4):6556-68. PubMed ID: 24747592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
    J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
    Ma LN; Ma Y; Luo X; Ma ZM; Ma LN; Ding XC
    Sci Rep; 2024 May; 14(1):12149. PubMed ID: 38802416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
    Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
    Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
    Kim SH; Ahn S; Park CK
    Hepatobiliary Pancreat Dis Int; 2012 Feb; 11(1):51-9. PubMed ID: 22251470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
    Fang CY; Lin YH; Chen CL
    J Oral Pathol Med; 2019 Sep; 48(8):712-719. PubMed ID: 31237374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.